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Summary
Study design: As part of a large screening study of perinatal depres-
sion, pregnant women were screened for demographic, depression and
treatment variables in obstetrics clinics. Women taking antidepressant
medication prior to conception were included in the sample as the
study aimed to document rates of antidepressant medication use, and
relationship to depressive symptomatology.
Results: Among women who reported using antidepressant medica-
tions within 2 years prior to screening (n¼ 390, or 11% of all women),
22% reported current use of these medications. Women who reported
using antidepressant medications (52%) and those who discontinued
them (49%) evidenced elevated depressive symptoms during pregnancy.
Conclusions: Both women who discontinue and some who continue
antidepressants during pregnancy demonstrate depressive symptoms,
suggesting sub-optimal management of both groups. Future studies
should carefully assess the adequacy of treatments prescribed as well
as the monitoring and adherence of recommended treatments. Full
symptom remission should be the goal for antenatal and postnatal
depression in order to minimize risk to mother and baby.
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Introduction
Depression is one of the most common conditions to
complicate pregnancy. One systematic recent study sug-
gests that 10% of gravid women meet criteria for major
depressive disorder (Cohen and Rosenbaum, 1998).
Untreated depression is an important risk factor for unfa-
vorable pregnancy outcomes. These include poor weight
gain, lack of prenatal care, and substance abuse (Miller,
1991). Human studies demonstrate that perceived life-
event stress, as well as depression and anxiety in preg-
nancy predicted lower infant birth weight, decreased
Apgar scores, prematurity and smaller head circum-
ference (Steer et al., 1992; Zuckerman et al., 1990;
Sandman et al., 1994).
While depression poses threats to a pregnancy, deci-
sions about antidepressant treatment during pregnancy,
remains a common obstetric conundrum. Because depres-
sion so often presents in childbearing years, women are
often taking antidepressant medications at the time of
conception. The bulk of the literature suggests that the
tricyclic antidepressants and selective serotonin reuptake
inhibitors (SSRI’s) are unlikely to contribute to major
congenital anomalies when used in pregnant women
(Altshuler et al., 1996; Pastuszak et al., 1993; Kulin
et al., 1998). Careful monitoring of women using antide-
pressants during pregnancy is essential. Earlier studies
with the tricyclic antidepressants suggested that as mater-
nal plasma volumes increased, antidepressant blood levels
fall with consequent re-emergence of mood symptoms
during later pregnancy (Altshuler and Hendrick, 2000).
While plasma levels of the SSRI’s are not frequently
monitored, it is a common clinical phenomenon to ob-
serve increases in mood symptomatology in the late 2nd
and 3rd trimester, which responds to increasing doses of
the antidepressant medication.
This study examined the rates of recent and current
antidepressant medication and their relationship to mood
symptoms as measured by the CES-D administered in
the waiting areas of obstetrics clinics.
Material and methods
Procedures
As part of a larger pregnancy screening and intervention proj-
ect which took place from February 2000 through January 2002,
a total of 390 pregnant women were identified who had used
antidepressant medication within two years prior to conception.
The majority of women approached (90%) agreed to complete
the screening questionnaire. Confidentiality was maintained and
all study procedures were approved by the University of
Michigan Medical School Institutional Review Board.
Participants
The mean age of participants was 28.6 (s.d.¼ 6) years. Most
were married (74%), others had a live-in partner (10%), were
separated (1.3%), divorced (1.8%), widowed (0.1%), never mar-
ried (12.8%). The racial distribution of the sample reflected
that of southeast lower Michigan based on the 2000 Census data
and were as follows: 73% Caucasian, 13% African American,
9.3% Asian, 2.4% Hispanic, 0.7% Native American, and 1.6%
‘‘other’’ race. Women were screened at an average of 24
gestational weeks (s.d.¼ 10.4).
Measures
The screening questionnaire consisted of items assessing demo-
graphic and depression related variables. Women were ques-
tioned regarding their antidepressant medication use in the
past 2 years and whether they had discontinued medication as
a result of the pregnancy. Depressive symptomatology was mea-
sured by the Center for Epidemiological Studies Depression
Scale (CES-D). The CES-D is used widely as a depression
screening instrument in non-clinical populations, with good cor-
relation to the Beck Depression Inventory (Beck et al., 1961).
The standard cut-off point of 16 was used to determine signifi-
cant elevated depressive symptomatology.
Data analyses
The primary analyses for this study are focused exclusively on
women who reported that they had taken medications for treat-
ment of depression in the two years prior to the screening date
(n¼ 390, 11% of all pregnant women screened). Two groups
emerged: women who reported that they had discontinued use of
these medications, thus were not currently taking them (n¼ 248)
and women who continued to use antidepressant medications
while pregnant (n¼ 68). Women who omitted information on
whether they were currently using antidepressant medications
were not included in this grouping (n¼ 74). T-test was used to
examine group differences between the women who were not
taking antidepressant medications and those who were taking
antidepressants in CES-D total scores. Chi-square analysis was
used to examine the relationship between antidepressant medi-
cation use (yes=no) and elevated CES-D (scores <16 vs scores
16). A CES-D cutoff score of 22 was also examined in this
manner, with similar results.
Results
Overall, 11% of all women screened reported use of
antidepressant medications in the past 2 years. Among
the 316 women who reported use of antidepressant med-
ication in the 2 years prior to completing the screening
measure (and provided current medication data), 78%
(n¼ 248) reported no current use of antidepressant med-
ications in pregnancy, and 68 (22%) reported current
use of these medications. A subgroup of women who
recently discontinued antidepressant medications (57%,
n¼ 141 out of 248) reported that they discontinued as a
direct result of conception. Many women not taking
antidepressant medications during pregnancy (who had
used these medications in the past 2 years) evidenced
depressive symptomatology during pregnancy, with 49%
having elevated CES-D scores (i.e.  a score of 16) at
the point of screening. 52% of those taking medications
showed elevated CES-D. No significant differences on
elevated CES-D were found between those taking and
not taking antidepressant medications during pregnancy
(based on Chi-square test). Both groups of women
showed mean elevated CES-D scores (group taking med-
ications mean CES-D¼ 17.4, s.d.¼ 11.6; group not tak-
ing medications mean CES-D¼ 18.3, s.d.¼ 12.4), with
no difference found between the groups based on t-test
results. When the CES-D was examined after omitting 3
items that pertain to difficulties with sleep, appetite and
energy (symptoms that may be confounded with preg-
nancy related experiences), the results were similar.
Discussion
These data show that, regardless of antidepressant medi-
cation use in pregnancy, many women with recent use of
antidepressant medications (i.e. prior 2 years) showed
elevated symptoms of antenatal depression. Medication
discontinuation was associated with high prevalence of
depressive symptoms, with 49% of non-medicated
women having elevated CES-D. It is also noteworthy that
even women who continued medication did not have
complete quiescence of their mood symptoms. These
findings suggest that, among a sample of women screened
in obstetrics settings, adequate remission of symptoms is
not being achieved.
In this project, we were not able to assess the reasons
for incomplete symptom remission among women who
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reported current use of antidepressant medications. It
is possible that poor treatment adherence and=or inade-
quate prescribing or monitoring of symptoms and med-
ication management may be implicated. In a related
study, Cohen and colleagues (2002) found that relapse
rates were much higher in unmedicated women. How-
ever, in that study medicated women were monitored
within more highly structured psychiatric outpatient
settings. Further information about the antidepressant
treatment regimen, antidepressant blood levels and con-
current therapies would be essential to better understand
the adequacy of the medication treatments.
When medicated, women should be closely monitored
for persistent symptoms despite use of antidepressants or
other treatments. Physicians treating pregnant women at
risk for depression could monitor such symptoms using
a symptom severity measure such as the Beck Depres-
sion Inventory prior to office visits each trimester, mak-
ing pharmacotherapy adjustments accordingly. It is not
clear from this study whether obstetricians were aware
of their patients’ use or non-use of antidepressant med-
ications, their depression risk or other forms of mental
health service use. Most of the women who discontinued
medication were not in mental health treatment, and
unlikely to have been engaging in prevention strategies
or receiving regular medication visits or adjunctive
psychotherapy.
This is one of the few studies to document the rates
of antidepressant medication use around the time of
conception, and rates of discontinuing these medicines
due to conception. There are several practical and meth-
odological difficulties inherent in a large screening study
such as this. This study relied on self-reports of medi-
cation discontinuation and mood symptoms. Although
every effort was made to increase accuracy of reporting
(assurance of confidentiality and not notifying clinicians
about study data), future studies should include other
objective measures of mood and mood treatment, such
as inspection of medical records and of pharmacy data.
Finally, more data about those women choosing to con-
tinue their antidepressant medication would have been
informative. Specifically, those blood values correlating
with rates of breakthrough symptoms of depression, fre-
quency of medication monitoring, information about
medication adherence, and what types of psychological
treatment the women were receiving may have helped
determine which factors contributed to these break-
through symptoms. Studies employing careful assess-
ment of these important factors are needed.
Both women who continue medication and those who
discontinue their antidepressants during pregnancy merit
close follow-up to ensure full remission of symptoms.
Minimizing risk to the fetus is paramount, and there may
be increased risks inherent in exposing the fetus simul-
taneously to sub-therapeutic levels of medication and to
depressive symptomatology throughout the pregnancy.
All decisions regarding medication in pregnancy must
consider the risks of fetal exposure, the risks of untreated
psychiatric illness in the mother and the risks of relapse
when maintenance medications are discontinued.
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